Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
The Ted Rogers Centre for Heart Research is thrilled to welcome Dr. Cedric Manlhiot as the inaugural Rogers Innovator of Cardiovascular Precision Medicine at SickKids. In addition to his role at TRCHR, Dr. Manlhiot will be a Scientist in the Translational Medicine...
Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
Launching in March 2024, emergency department (ED) physicians at the University Health Network (UHN) can now access the Emergency Heart Failure Mortality Risk Grade (EHMRG) calculator within Epic, UHN’s electronic medical record. The EHMRG score estimates the risk of...
Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
Few technologies have the potential to disrupt and eliminate infectious disease and viral infections– but gene editing, CRISPR in particular, is a latent technology that could change biotech – and we’re just seeing the beginning of what effect it could have on the world.
With scientific promise comes interest from investors – a surge of biotech startups are utilizing CRISPR technology for many different applications such as at-home testing, in-clinic uses, and more. “This incredibly powerful repurposing of the bacterial immune system has created an outpouring of financial backing for small companies with revolutionary technological advancement in genome engineering-based ventures.”[1]
On November 12th, the event will explore this subject with presentations from experts in the field, startup companies innovating in this space, and investors looking to invest in these new applications. The event will also be viewed via live stream.